

HCM SCD risk algorithm cost-effectiveness analysis

Nathan Green, Yang Chen

09/11/2020

0.1 Introduction

Sudden cardiac death (SCD) risk score algorithm details see (O'Mahony et al. 2014).

There have been previous cost-effectiveness analyses of ICD implants (Magnusson and Wimo 2020; Boriani et al. 2014; Bryant et al. 2007; Caro et al. 2007; Cowie et al. 2009; García-Pérez et al. 2015; Mealing et al. 2016; Sanders, Hlatky, and Owens 2005; Smith et al. 2013)

Cost-effectiveness of a cardiovascular risk prediction algorithm. (Zomer et al. 2017) for statins interventions and people with severe mental illness.

(Yao et al. 2007) use a Markov model and consider multiple implantations attempts if unsuccessful. (Colquitt et al. 2014) is a Health Technology Assessment which compares optimal pharmacological therapy (OPT) with or without ICD. (Tomini 2016) is a review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure. (Ommen et al. 2020) 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy.



0.2 Data

The main data set contains $n = 3672$ individuals follow-up data of patients with HCM who may have been given an ICD due to some risk decision. Key cohort characteristics include the following. Patients were enrolled from the 6 health centres: Athens (474), Bologna (456), Coruna (590), London (1592), Murcia (404), Naples (156); The amount of censoring was 0 (3475), 1 (197); The mean age (sd) was 48 (16); The start of study data collection was in 1972 to 2011. Further plots are given in the Appendix. See (O'Mahony et al. 2014) for further details.

Health and cost data were obtained from literature and expert opinion. What values we wish to use will determine the form of the state model. For instance, if cost are only accrued on entry to a state then we may use a tunnel state. If cost depend on the patient history then we may need to duplicate a state.

Table 1 gives the unit cost and health values used in the model.

Table 1: Model parameter values. *either one-off/on state entry or recurring.

Description	Parameter	Value*	Range	Source
<i>Health</i>				
Manage with ICD	q_icd	0.637 QALY/year		Noyes et al. (2007)
Implantation procedure utility	u_implant	-0.016		Smith et al. (2013)
Shock utility	u_shock	-0.5		
HCM without ICD	q_hcm	1 QALY/year		
Death	q_death	0 QALY/year		
<i>Cost</i>				
ICD appointment	c_appt	£10		

Description	Parameter	Value*	Range	Source
Perform risk score	c_rs	£20?		
Implant ICD	c_implant	£4,666		EY02B Tariffs
Implant replacement	c_repl	£45,000		
Implant complication	c_compl	£28,839		Smith et al. (2013)
Non-fatal shock	c_shock	£22,880		UK Stroke Assoc.
HCM without ICD	c_hcm	0		
SCD	c_scd	0		
All-cause death	c_death	0		
<i>Probabilities</i>				
Initial implant complication	p_compl	0.047		Smith et al. (2013)
Replacement implant complication	p_repl	0.032		Smith et al. (2013)
Time horizon	T	12 years		
Implant replacement	t_repl	10 years		
Annual number of appointments	n_appt	2		

Table 2 gives the starting state populations for non-zero states.

Table 2: Starting state populations by decision rule.

Risk rule	State	Population
Observed	HCM ICD	559
-	HCM	3113
Score > 4%	HCM ICD	2561
-	HCM	1111
Score > 6%	HCM ICD	542
-	HCM	3130
Risk factor >0	HCM ICD	1785
-	HCM	1887
Risk factor >1	HCM ICD	481
-	HCM	3191
Risk factor >2	HCM ICD	78
-	HCM	3594

0.3 Methods

The individual-level patient data are first stratified in to two groups for each risk algorithm. These are

- Partition observed in data set
- ICD given if number of risk factors > 0, 1 or 2
- ICD given if risk score > 6%
- ICD given if risk score > 4%

We included the option of a fuzzy decision boundary such that near the threshold there is some random variation as to whether a patient received an ICD or not.

0.3.1 Markov model



Th patient data give us starting state populations for HCM with ICD and HCM without ICD which will be different for each risk decision rule. Further, the transition probabilities from these states will differ because of the case mixes.

A diagram of the current cohort model is given in Figure 1.




Figure 1: Markov model diagram. Bold circles represent starting states and dashed circles represent sink states.

Assuming that shocked patients return to the HCM ICD state then the transition matrix looks like the following.

$$\begin{pmatrix} p_{11} & p_{12} & 0 & 0 & p_{15} \\ 1 & 0 & 0 & 0 & 0 \\ 0 & 0 & p_{33} & p_{34} & p_{35} \\ 0 & 0 & 0 & 1 & 0 \\ 0 & 0 & 0 & 0 & 1 \end{pmatrix}$$

We have used a year step size but if e.g. cost are accrued at different intervals then this can be adapted. The time horizon is set at 12 years from time of implant.

0.3.2 State health and cost equations

Model assumptions include the following: We assume that an ICD patient has 2 annual appointments. All shocks are treated the same in terms of costs and health impact. Implantation can have complications and the cost of an implant complication is taken as a weighted sum of infection and dislodgement cost with values from (Smith et al. 2013). Subscript s denotes the state number and superscript denotes the intervention either ICD or not.

• Annual health:

$$\begin{aligned} e_{s=1}^i(t) &= q_icd, \quad i = 1, 2 \\ e_{s=3}^i(t) &= q_hcm, \quad i = 1, 2 \\ e_{s=2}^i(t) &= q_hcm - u_shock, \quad i = 1, 2 \\ e_s^i(t) &= 0, \quad i = 1, 2, \quad s = 4, 5 \end{aligned}$$

- Initial:

$$\begin{aligned} c_{s=1}^0(t=0) &= c_icd + p_compl \times c_compl \\ c_{s=1}^1(t=0) &= c_icd + c_rscore + p_compl \times c_compl \end{aligned}$$

should we include this?

$$e_{s=1}^i(t=0) = q_hcm - u_implant - p_compl \times u_compl, \quad i = 1, 2$$

- Annual cost:

$$\begin{aligned} c_{s=1}^i(t) &= 2c_appt, \quad i = 1, 2, \quad t \neq t_repl \\ c_{s=2}^i(t) &= c_shock, \quad i = 1, 2 \end{aligned}$$

- Implant replacement

$$c_{s=1}^i(t) = 2c_appt + c_repl + p_compl \times c_compl, \quad i = 1, 2, \quad t = t_repl$$

should we include this?

$$e_{s=1}^i(t) = q_icd - p_compl \times u_compl, \quad i = 1, 2, \quad t = t_repl$$

0.3.2.1 Transition probability inference Using WinBUGS (Zhang 2014) called from R, each new data set is used to generate posterior samples of transition probabilities. Denote x as the observed number of transitions, p the probability of a transition and n as the total number of transitions from a given state. The hyperparameters α characterise the prior knowledge on p . Superscripts indicate the decision rule used.

$$x_{i.}^{(1)} \sim \text{Multinomial}(p_{i.}^{(1)}, n_i^{(1)}), \quad i = 1, 3$$

$$x_{i.}^{(2)} \sim \text{Multinomial}(p_{i.}^{(2)}, n_i^{(2)}), \quad i = 1, 3$$

$$p_{i.}^{(1)} \sim \text{Dirichlet}(\alpha^{(1)}), \quad i = 1, 3$$

$$p_{i.}^{(2)} \sim \text{Dirichlet}(\alpha^{(2)}), \quad i = 1, 3$$

For all sink states,

$$p_{ij}^{(s)} = \begin{cases} 1 & \text{if } i = j; \\ 0 & \text{if } i \neq j. \end{cases}$$

0.4 Results

We give results of the model fitting and cost-effectiveness analysis.

0.4.1 Model fitting

Figures 2 and 3 give histograms of posterior distributions for state transition probabilities for no groups without and with ICD implants.

Figure 4 gives an example of state occupancy over time plot. This shows that for the new algorithm there are fewer SCD and more shocks.

0.4.2 Cost-effectiveness




Figure 2: Histogram of posterior distributions for state transition probabilities.




Figure 3: Histogram of posterior distributions for state transition probabilities.




Figure 4: State occupancy over time.

Table 3: Cost-effectiveness statistics per enrolled study individual.

Strategy	Cost, c (£)	Δc (£)	QALYs, e	Δe	ICER (£/QALY)
Baseline	7912.41		10.29		
> 6%	7484.34	-428.07	10.39	0.09	-4696
> 4%					
> 1 risk factor					
> 2 risk factors					

Figure 5 gives the CEAC and Figure 6 gives the CE-plane.




Figure 5: Cost-effectiveness acceptability curve (CEAC).

0.5 Discussion

Decision making as to whether have the implant is shared between patient and medical professional. The SCD risk score is a support tool which contributes to the final decision. An SCD risk score of 6% is treatment recommendation for one patient versus another. There could be individual preferences that out-weighs the risk score and mean a patient chooses the alternative.

Having more robust quality of life data will help to make such decisions. more embedded PROMs research Informatics Consult (Lai et al. 2021) automation to scale evidence generation and to accelerate the return of results within clinical time-scales.




Figure 6: Cost-effectiveness plane.

We did not include CRT-D or s-ICD but that can be overcome by sensitivity analyses that show e.g. the main message is that conclusions about the ICER etc will be robust to most departures from base assumptions other than tweaks in utility (which are the part of the model based on the weakest data!)

(Olivotto et al. 2020) The role of new DMARDs and their ability to influence quality of life. So if both ICD and non-ICD patients experience significant increases in QoL, are these equally distributed?

1 Appendix




Figure 7: Year of study entry bar plot.

References

- Boriani, Giuseppe, Paolo Cimaglia, Mauro Biffi, Cristian Martignani, Matteo Ziacchi, Cinzia Valzania, and Igor Diemberger. 2014. “Cost-effectiveness of implantable cardioverter-defibrillator in today’s world.” *Indian Heart Journal* 66 (SUPPL. 1): S101–4. <https://doi.org/10.1016/j.ihj.2013.12.034>.
- Bryant, Jackie, Hakan Brodin, Emma Loveman, and Andrew Clegg. 2007. “Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation.” *International Journal of Technology Assessment in Health Care* 23 (1): 63–70. <https://doi.org/10.1017/S0266462307051586>.
- Caro, J. Jaime, Alexandra Ward, H. Baris Deniz, Judith A. O’Brien, and Jenifer L. Ehreth. 2007. “Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.” *Value in Health* 10 (1): 13–22. <https://doi.org/10.1111/j.1524-4733.2006.00140.x>.
- Colquitt, Jill L, Diana Mendes, Andrew J Clegg, Petra Harris, Keith Cooper, Joanna Picot, and Jackie Bryant. 2014. “Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.” *Health Technology Assessment* 18 (56). <https://doi.org/10.3310/hta18560>.
- Cowie, Martin R., Deborah Marshall, Michael Drummond, Nicole Ferko, Michael Maschio, Matthias Ekman, Luc De Roy, et al. 2009. “Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: Results of markov modelling in a european population.” *Europace* 11 (6): 716–26. <https://doi.org/10.1093/europace/eup068>.
- García-Pérez, Lidia, Pilar Pinilla-Domínguez, Antonio García-Quintana, Eduardo Caballero-Dorta, F. Javier

- García-García, Renata Linertová, and Iñaki Imaz-Iglesia. 2015. "Economic evaluations of implantable cardioverter defibrillators: a systematic review." *European Journal of Health Economics* 16 (8): 879–93. <https://doi.org/10.1007/s10198-014-0637-x>.
- Lai, Alvina G, Wai Hoong Chang, Constantinos A Parisinos, Michail Katsoulis, M Ruth, Anoop D Shah, Vincent Nguyen, et al. 2021. "An Informatics Consult approach for generating clinical evidence for treatment decisions." *medRxiv*. <https://doi.org/https://doi.org/10.1101/2021.01.10.21249331>.
- Magnusson, Peter, and Anders Wimo. 2020. "Health economic evaluation of implantable cardioverter defibrillators in hypertrophic cardiomyopathy in adults." *International Journal of Cardiology* 311: 46–51. <https://doi.org/10.1016/j.ijcard.2020.02.055>.
- Mealing, Stuart, Beth Woods, Neil Hawkins, Martin R. Cowie, Christopher J. Plummer, William T. Abraham, John F. Beshai, Helmut Klein, and Mark Sculpher. 2016. "Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure." *Heart* 102 (21): 1742–49. <https://doi.org/10.1136/heartjnl-2015-308883>.
- Noyes, Katia, Ethan Corona, Jack Zwanziger, W. Jackson Hall, Hongwei Zhao, Hongkun Wang, Arthur J. Moss, and Andrew W. Dick. 2007. "Health-related quality of life consequences of implantable cardioverter defibrillators: Results from MADIT II." *Medical Care* 45 (5): 377–85. <https://doi.org/10.1097/01.mlr.000.0257142.12600.c1>.
- O'Mahony, Constantinos O, Fatima Jichi, Menelaos Pavlou, Lorenzo Monserrat, Aristides Anastasakis, Claudio Rapezzi, Elena Biagini, et al. 2014. "Myocardial disease A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)." *European Heart Journal* 35: 2010–20. <https://doi.org/10.1093/eurheartj/eh439>.
- Olivotto, Iacopo, Artur Oreziak, Roberto Barriales-Villa, Theodore P. Abraham, Ahmad Masri, Pablo Garcia-Pavia, Sara Saberi, et al. 2020. "Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial." *The Lancet* 396 (10253): 759–69. [https://doi.org/10.1016/S0140-6736\(20\)31792-X](https://doi.org/10.1016/S0140-6736(20)31792-X).
- Ommen, Steve R., Seema Mital, Michael A. Burke, Sharlene M. Day, Anita Deswal, Perry Elliott, Lauren L. Evanovich, et al. 2020. "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy." *Circulation* 142 (25). <https://doi.org/10.1161/cir.0000000000000937>.
- Sanders, Gillian D, Mark A Hlatky, and Douglas K Owens. 2005. "Cost-Effectiveness of Implantable Cardioverter–Defibrillators," 1471–80.
- Smith, Tim, Luc Jordaens, Dominic A. M. J. Theuns, Pascal F. Van Dessel, Arthur A. Wilde, and M. G. Myriam Hunink. 2013. "The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: A European analysis." *European Heart Journal* 34 (3): 211–19. <https://doi.org/10.1093/eurheartj/ehs090>.
- Tomini, F. 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure." *Eur J Health Econ*, 1159–72. <https://doi.org/10.1007/s10198-015-0752-3>.
- Yao, Guiqing, Nick Freemantle, Melanie J Calvert, Stirling Bryan, Jean-claude Daubert, and John G F Cleland. 2007. "The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator." *European Heart Journal*, 42–51. <https://doi.org/10.1093/eurheartj/ehl382>.
- Zhang, Zhiyong. 2014. "WebBUGS: Conducting Bayesian statistical analysis online." *Journal of Statistical Software* 61 (7): 1–30. <https://doi.org/10.18637/jss.v061.i07>.
- Zomer, Ella, David Osborn, Irwin Nazareth, Ruth Blackburn, Alexandra Burton, Sarah Hardoon, Richard Ian, et al. 2017. "Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE)." *BMJ Open*, 1–11. <https://doi.org/10.1136/bmjopen-2017-018181>.